SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Manogna Nookathota, Sandeep Mukherjee, Antiviral therapy for chronic hepatitis C in 2014, Expert Review of Clinical Pharmacology, 2014, 7, 4, 499

    CrossRef

  2. 2
    Maximilian David Schneider, Christoph Sarrazin, Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?, Antiviral Research, 2014, 105, 64

    CrossRef

  3. 3
    Linzhi Chen, Roger St. George, Stephen H. Norris, Yanping Mao, Elsy Philip, Li-Quan Wang, Diana Wu, Michael J. Potchoiba, Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats, Xenobiotica, 2014, 1

    CrossRef

  4. 4
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  5. 5
    Gregory Everson, Curtis Cooper, Christophe Hézode, Mitchell L. Shiffman, Eric Yoshida, Teresita Beltran-Jaramillo, Pietro Andreone, Savino Bruno, Peter Ferenci, Stefan Zeuzem, Michael Brunda, Sophie Le Pogam, Isabel Nájera, Julian Zhou, Mercidita T. Navarro, Athina Voulgari, Nancy S. Shulman, Ellen S. Yetzer, DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4, Liver International, 2014, 34, 9
  6. 6
    William L. Irving, Daniel Rupp, C. Patrick McClure, Lwin Mar Than, Andrew Titman, Jonathan K. Ball, Eike Steinmann, Ralf Bartenschlager, Thomas Pietschmann, Richard J.P. Brown, Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region, Antiviral Research, 2014, 110, 52

    CrossRef

  7. 7
    Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, Maxwell D. Cummings, Oliver Lenz, Pierre Raboisson, Kenny Simmen, Sandrine Vendeville, Herman de Kock, Magnus Nilsson, Andras Horvath, Ronald Kalmeijer, Guy de la Rosa, Maria Beumont-Mauviel, Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor, Journal of Medicinal Chemistry, 2014, 57, 5, 1673

    CrossRef

  8. 8
    Sarah Tischer, Robert J. Fontana, Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting, Journal of Hepatology, 2014, 60, 4, 872

    CrossRef

  9. 9
    Isabel Fofana, Nikolaus Jilg, Raymond T. Chung, Thomas F. Baumert, Entry inhibitors and future treatment of hepatitis C, Antiviral Research, 2014, 104, 136

    CrossRef

  10. 10
    Natalia Lorna Laufer, Jürgen Kurt Rockstroh, Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV, Expert Review of Anti-infective Therapy, 2014, 12, 2, 157

    CrossRef

  11. You have free access to this content11
    Raymond Schinazi, Philippe Halfon, Patrick Marcellin, Tarik Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, 2014, 34,
  12. You have free access to this content12
    Mitchell L. Shiffman, Yves Benhamou, HCV F1/F2 patients: treat now or continue to wait, Liver International, 2014, 34,
  13. 13
    Kian Bichoupan, Douglas T. Dieterich, Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals, Drugs, 2014, 74, 9, 951

    CrossRef

  14. 14
    Mitchell L. Shiffman, Hepatitis C virus therapy in the direct acting antiviral era, Current Opinion in Gastroenterology, 2014, 30, 3, 217

    CrossRef

  15. 15
    Tae Hun Kim, June Sung Lee, Recent Advancement in the Treatment of Chronic Hepatitis C, Korean Journal of Medicine, 2014, 86, 5, 563

    CrossRef

  16. 16
    Eric J Lawitz, Fernando E Membreno, Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects, Journal of Gastroenterology and Hepatology, 2014, 29, 8
  17. You have free access to this content17
    M. H. Miller, K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski, J. F. Dillon, Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2014, 39, 12
  18. 18
    Kentaro Matsuura, Tsunamasa Watanabe, Yasuhito Tanaka, Role of IL28B for chronic hepatitis C treatment toward personalized medicine, Journal of Gastroenterology and Hepatology, 2014, 29, 2
  19. 19
    Shuhei Nishiguchi, Yoshiyuki Sakai, Makoto Kuboki, Satoshi Tsunematsu, Yasuhisa Urano, Wataru Sakamoto, Yasuhiro Tsuda, Gerhard Steinmann, Masao Omata, Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection, Liver International, 2014, 34, 1
  20. You have free access to this content20
    Tarik Asselah, Patrick Marcellin, Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir, Liver International, 2014, 34,
  21. 21
    Michael P. Manns, John M. Vierling, Bruce R. Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita Y.M. Howe, Christine Fandozzi, Jacqueline Gress, Christopher L. Gilbert, Peter M. Shaw, Michael P. Cooreman, Michael N. Robertson, Peggy Hwang, Frank J. Dutko, Janice Wahl, Niloufar Mobashery, The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis, Gastroenterology, 2014, 147, 2, 366

    CrossRef

  22. 22
    Parth J Parekh, Mitchell L Shiffman, The role of interferon in the new era of hepatitis C treatments, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 649

    CrossRef

  23. You have free access to this content23
    Valérie Martel-Laferrière, Douglas T. Dieterich, Treating HCV in HIV 2013: on the cusp of change, Liver International, 2014, 34,
  24. 24
    Danushka Kumara Wijesundara, Yang Xi, Charani Ranasinghe, Unraveling the Convoluted Biological Roles of Type I Interferons in Infection and Immunity: A Way Forward for Therapeutics and Vaccine Design, Frontiers in Immunology, 2014, 5,

    CrossRef

  25. 25
    Timothy A. Stammers, René Coulombe, Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, Sylvie Goulet, Araz Jakalian, Steven LaPlante, Jean Rancourt, Bounkham Thavonekham, Dominik Wernic, George Kukolj, Pierre L. Beaulieu, Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 24, 6879

    CrossRef

  26. 26
    Jennifer J. Kiser, James R. Burton, Gregory T. Everson, Drug–drug interactions during antiviral therapy for chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 10, 596

    CrossRef

  27. 27
    Jürgen K Rockstroh, Sanjay Bhagani, Managing HIV/hepatitis C co-infection in the era of direct acting antivirals, BMC Medicine, 2013, 11, 1, 234

    CrossRef

  28. 28
    J S Au, P J Pockros, Novel Therapeutic Approaches for Hepatitis C, Clinical Pharmacology & Therapeutics, 2013, 95, 1, 78

    CrossRef

  29. 29
    Mohamed A Daw, Hana A Elasifer, Aghnaya A Dau, Mohamed Agnan, The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya, Virology Discovery, 2013, 1, 1, 3

    CrossRef